| Patents for A61P 43 - Drugs for specific purposes, not provided for in groups (156,317) |
|---|
| 04/03/2001 | US6210926 Activating apoptosis in cell infected with herpes by in vitro administration of agent that inhibits infected cell protein-4 function |
| 04/03/2001 | US6210913 Modulation of integrin-mediated signal transduction |
| 04/03/2001 | US6210670 Cross-reacting monoclonal antibodies specific for E-selectin and P-selectin |
| 04/03/2001 | CA2211120C Lineage-directed induction of human mesenchymal stem cell differentiation |
| 04/01/2001 | CA2321593A1 .alpha.-sulfonylamino hydroxamic acid inhibitors of matrix metalloproteinases for the treatment of peripheral or central nervous system disorders |
| 03/30/2001 | WO2003044525A1 Targeting cells having mad2 mutation for treatment and/or prevention of disease |
| 03/30/2001 | WO2002090588A1 Interfering with telomere maintenance in treatment of diseases |
| 03/30/2001 | CA2321379A1 Bicyclic pyrrolyl amides as glycogen phosphorylase inhibitors |
| 03/29/2001 | WO2001022092A2 Method to identify compounds which modulate fra-1 expression fils |
| 03/29/2001 | WO2001022090A1 Method for identifying compounds useful in the therapy of bone disorders |
| 03/29/2001 | WO2001022078A1 Method and device for detecting and isolating pharmacological compounds being contained in substance mixtures |
| 03/29/2001 | WO2001021793A1 p21Cip1 REMEDIES FOR RHEUMATISM |
| 03/29/2001 | WO2001021787A1 Polypeptide humanin inhibiting nerve cell death |
| 03/29/2001 | WO2001021786A1 Method of screening disease depressant gene |
| 03/29/2001 | WO2001021784A2 Pcna-associated cell cycle proteins, compositions and methods of use |
| 03/29/2001 | WO2001021773A2 Human endothelin converting enzyme-like proteins and polynucleotides encoding the same |
| 03/29/2001 | WO2001021771A2 Compositions and methods for inhibiting g2 cell cycle arrest and sensitizing cells to dna damaging agents |
| 03/29/2001 | WO2001021761A2 Recombinant adenoviral vectors and their utility in the treatment of various types of fibrosis: hepatic, renal, pulmonary, as well as hypertrophic scars |
| 03/29/2001 | WO2001021663A1 Pcna associated cell cycle proteins, compositions and methods of use |
| 03/29/2001 | WO2001021651A2 Novel human protease inhibitor-like proteins and polynucleotides encoding the same |
| 03/29/2001 | WO2001021648A1 Uses of kappa-conotoxin pviia |
| 03/29/2001 | WO2001021628A1 A substantially cell membrane impermeable compound and use thereof |
| 03/29/2001 | WO2001021620A2 Amine derivatives of benzo-4,5-thieno-2,3-d pyrimidines |
| 03/29/2001 | WO2001021619A1 N-substituted 4-aminopteridines, synthesis and use thereof as pharmaceutical agent |
| 03/29/2001 | WO2001021615A1 Benzimidazole derivatives |
| 03/29/2001 | WO2001021614A1 5-aminoalkyl and 5-aminocarbonyl substituted indoles |
| 03/29/2001 | WO2001021605A2 Method for extracting compounds of furan lipids and polyhydroxylated fatty alcohols of avocado, composition based on said compounds and use of said compounds in therapy, cosmetics and food |
| 03/29/2001 | WO2001021600A1 Caspase inhibitor |
| 03/29/2001 | WO2001021597A1 Therapeutic quinazoline derivatives |
| 03/29/2001 | WO2001021596A1 Quinazoline derivatives and their use as pharmaceuticals |
| 03/29/2001 | WO2001021595A1 Quinazoline derivatives |
| 03/29/2001 | WO2001021594A1 Quinazoline compounds and pharmaceutical compositions containing them |
| 03/29/2001 | WO2001021593A1 New benzimidazolone derivatives having mixed serotonine and dopamine receptors affinity |
| 03/29/2001 | WO2001021591A1 Pyrazole derivatives |
| 03/29/2001 | WO2001021590A1 Muscarinic antagonists |
| 03/29/2001 | WO2001021589A2 Mono- and bis-indolylquinones and prophylactic and therapeutic uses thereof |
| 03/29/2001 | WO2001021584A1 Tyrosine derivatives |
| 03/29/2001 | WO2001021583A1 Hydroxamic acid derivatives, process for the production thereof and drugs containing the same as the active ingredient |
| 03/29/2001 | WO2001021582A1 Biphenyl derivatives used as nhe-3 inhibitors |
| 03/29/2001 | WO2001021578A1 O-anisamide derivatives |
| 03/29/2001 | WO2001021575A1 Anti-inflammatory nitro- and thia- fatty acids |
| 03/29/2001 | WO2001021259A2 Use and compositions for treating platelet-related disorders using anagrelide |
| 03/29/2001 | WO2001021215A1 Cell based assay |
| 03/29/2001 | WO2001021214A1 Gene therapy for cerebrovascular disorders |
| 03/29/2001 | WO2001021204A1 Therapeutic uses of m3 polypeptide |
| 03/29/2001 | WO2001021191A2 Inhibition of abnormal cell growth with corticotropin-releasing hormone analogs |
| 03/29/2001 | WO2001021185A1 Novel pharmacological activities of curcuma longa extracts |
| 03/29/2001 | WO2001021182A1 Physical strength enhancing agents and glycogen accumulation promoting agents |
| 03/29/2001 | WO2001021180A1 Thrombopoietin mimetics |
| 03/29/2001 | WO2001021172A1 Anti-cancer nitro- and thia-fatty acids |
| 03/29/2001 | WO2001021171A1 Systems for agitated delivery of anti-infective compositions to treat disordered tissue such as cold sores |
| 03/29/2001 | WO2001021170A1 Systems for delivering anti-infective compositions from frangible ampules to treat disordered tissue such as cold sores |
| 03/29/2001 | WO2001021169A1 Mch antagonists |
| 03/29/2001 | WO2001021163A2 Methods and compositions for treating platelet-related disorders using mpl pathway inhibitory agents |
| 03/29/2001 | WO2001021156A1 Pharmaceutical chewing gum formulations |
| 03/29/2001 | WO2001021008A2 Method for increasing pet activity |
| 03/29/2001 | WO2001020998A1 Drug discovery using gene expression profiling |
| 03/29/2001 | WO2001020981A2 Anti-infective compositions for treating disordered tissue such as cold sores |
| 03/29/2001 | WO2001007067A3 Solutions and methods for inhibition of pain, inflammation and cartilage degradation |
| 03/29/2001 | WO2001002557A8 Neurotrophic factor receptor |
| 03/29/2001 | WO2001000612A3 Respiratory syncytial virus replication inhibitors |
| 03/29/2001 | WO2000075139A3 Benzothiazinone and benzoxazinone compounds |
| 03/29/2001 | WO2000073294A3 3-(arylsulfonylamino)-tetrahydrofuran-3-carboxylic acid hydroxamides |
| 03/29/2001 | WO2000059875A3 Novel inhibitors of formation of advanced glycation endproducts (age's) |
| 03/29/2001 | WO2000054761A3 Regulation of phospholipase d activity |
| 03/29/2001 | WO2000047583A8 Cyclic substituted fused pyrrolocarbazoles and isoindolones |
| 03/29/2001 | WO2000037487A8 αvβ6 INTEGRIN INHIBITORS |
| 03/29/2001 | WO2000020607A9 Chimaeric proteins between members of tgf-beta superfamily |
| 03/29/2001 | WO2000012741A9 Inducible expression system |
| 03/29/2001 | US20010000075 Neurotactin and uses therefor |
| 03/29/2001 | DE19946289A1 Benzodiazepin-Derivate, deren Herstellung und Anwendung Benzodiazepine derivatives, their production and use |
| 03/29/2001 | DE19945810A1 Substituierte Benzimidazolderivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel Substituted benzimidazole derivatives, processes for their preparation and their use as medicaments |
| 03/29/2001 | DE19945302A1 Biphenylderivate als NHE-3-Inhibitoren Biphenyl as NHE-3 inhibitors |
| 03/29/2001 | DE19944767A1 N-substituierte 4-Aminopteridine, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel N-substituted 4-Aminopteridine, processes for their preparation and their use as medicaments |
| 03/29/2001 | CA2387529A1 Biphenyl derivatives as nhe-3 inhibitors |
| 03/29/2001 | CA2387520A1 Amine derivatives |
| 03/29/2001 | CA2386767A1 Novel human protease inhibitor-like proteins and polynucleotides encoding the same |
| 03/29/2001 | CA2385813A1 Human endothelin converting enzyme-like proteins and polynucleotides encoding the same |
| 03/29/2001 | CA2385447A1 Pyrazole derivatives |
| 03/29/2001 | CA2385428A1 Novel pcna-associated cell cycle proteins, compositions and methods of use |
| 03/29/2001 | CA2385425A1 Pcna associated cell cycle proteins, compositions and methods of use |
| 03/29/2001 | CA2385377A1 Method to identify compounds useful in the therapy of bone disorders |
| 03/29/2001 | CA2385257A1 Compositions and methods for inhibiting g2 cell cycle arrest and sensitizing cells to dna damaging agents |
| 03/29/2001 | CA2385105A1 Mono- and bis-indolylquinones and prophylactic and therapeutic uses thereof |
| 03/29/2001 | CA2385047A1 Uses of kappa-conotoxin pviia |
| 03/29/2001 | CA2384928A1 Method for identifying compounds useful in the therapy of bone disorders |
| 03/29/2001 | CA2384829A1 Systems for agitated delivery of anti-infective compositions to treat disordered tissue such as cold sores |
| 03/29/2001 | CA2384816A1 Inhibition of abnormal cell growth with corticotropin-releasing hormone analogs |
| 03/29/2001 | CA2384296A1 Therapeutic quinazoline derivatives |
| 03/29/2001 | CA2384291A1 Quinazoline derivatives and their use as pharmaceuticals |
| 03/29/2001 | CA2384284A1 Quinazoline derivatives |
| 03/29/2001 | CA2384282A1 Quinazoline compounds and pharmaceutical compositions containing them |
| 03/29/2001 | CA2383598A1 Therapeutic uses of m3 polypeptide |
| 03/29/2001 | CA2383591A1 Cell based assay |
| 03/29/2001 | CA2383152A1 Agent for enhancing stamina and agent for promoting glycogen accumulation |
| 03/29/2001 | CA2383147A1 Mch antagonists |
| 03/29/2001 | CA2382547A1 Methods and compositions for treating platelet-related disosders |
| 03/29/2001 | CA2369515A1 Pharmaceutical chewing gum formulations |
| 03/29/2001 | CA2351482A1 Novel pharmacological activities of curcuma longa extracts |
| 03/29/2001 | CA2348906A1 Gene therapy for cerebrovascular disorders |